Contingent Value Rights - Year 1 payment obligation
Company: Core Scientific
The claim, verbatim
CVR holders receive at first testing date cash equal to pro rata share of lesser of $43,333,333 or difference between $260 million and fair market value of Corresponding New Common Stock
Source (primary)
Core Scientific 8-K/A filed 2024-01-25 (SEC EDGAR, sec_filing)
View cached copy (2026-08-31)Live source ↗
Quote: “at the first testing date, cash equal to such Payee's pro rata share (the " Year 1 Contingent Payment Obligation ") of the lesser of (a) $43,333,333.33 and (b) the difference between (1) $260,000,000 and (2) the fair market value of the Corresponding New Common Stock”
How we checked this
Checked on September 18, 2026. The cited source supports every part of this claim.
The filing describes the Year 1 CVR cash payment formula as stated in the claim.
Confirmed in the source:
- At the first testing date, CVR holders receive cash
- The payment equals each holder's pro rata share of the lesser of $43,333,333.33 or the difference between $260 million and the fair market value of the Corresponding New Common Stock
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312524014941/d735123d8ka.htm) in full (67,867 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific 8-K/A filed 2024-01-25
Quote: “at the first testing date, cash equal to such Payee's pro rata share (the " Year 1 Contingent Payment Obligation ") of the lesser of (a) $43,333,333.33 and (b) the difference between (1) $260,000,000 and (2) the fair market value of the Corresponding New Common Stock”